Tamoxifen has been recommended for
The MONALEESA-7 trial is evaluating ovarian function suppression with either tamoxifen or an aromatase inhibitor, with or without the CDK inhibitor ribociclib, as
1987 Mar;109(3):290-9
Tamoxifen is not used with ribociclib because tamoxifen can prolong the QTc
Globally, breast cancer is the most frequently diagnosed cancer in women, affecting an estimated 2
For women with stage IV breast cancer, systemic drug therapies are the main treatments
Introduction
Tamoxifen and raloxifene are the only drugs approved in the US to help lower the risk of breast cancer, although for some women, other drugs called aromatase inhibitors Abstract
The third-generation aromatase inhibitor letrozole inhibits estrogen production, and is more efficacious than the estrogen receptor inhibitor tamoxifen
The study design was such that responders remained on tamoxifen therapy; those who initially or subsequently progressed went on to ovarian ablation either by surgery or irradiation
Hormone therapy is also known as endocrine therapy
An emerging mechanism of endocrine resistance arose from aberrant
, 2020)
Tamoxifen was the first endocrine agent approved for metastatic breast cancer in 1977 [14]
Because of its clinical effectiveness [1] and low side-effect profile, it has become the treatment of first choice for patients with locally
It can prevent the cancer from returning or spreading elsewhere
In pre- and perimenopausal women with breast cancer, combining ribociclib (Kisqali) and hormone therapy was more effective at halting the growth of metastatic tumors than standard treatment with a combination of chemotherapy drugs
[1-3,41]However, the risk for high-grade endometrial cancers of poor prognosisis not increased with tamoxifen therapy